Dr. Reddy’s Laboratories Ltd. ADR (RDY) concluded trading on Thursday at a closing price of $13.27, with 3.05 million shares of worth about $40.52 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.52% during that period and on March 27, 2025 the price saw a loss of about -0.15%. Currently the company’s common shares owned by public are about 834.42M shares, out of which, 833.09M shares are available for trading.
Stock saw a price change of -2.28% in past 5 days and over the past one month there was a price change of 1.76%. Year-to-date (YTD), RDY shares are showing a performance of -15.96% which decreased to -9.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.50 but also hit the highest price of $16.89 during that period. The average intraday trading volume for Dr. Reddy’s Laboratories Ltd. ADR shares is 1.91 million. The stock is currently trading 1.50% above its 20-day simple moving average (SMA20), while that difference is down -2.06% for SMA50 and it goes to -11.40% lower than SMA200.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) currently have 834.42M outstanding shares and institutions hold larger chunk of about 14.57% of that.
The stock has a current market capitalization of $11.06B and its 3Y-monthly beta is at 0.52. PE ratio of stock for trailing 12 months is 17.26, while it has posted earnings per share of $0.77 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RDY, volatility over the week remained 1.10% while standing at 1.23% over the month.
Stock’s fiscal year EPS is expected to drop by -1.43% while it is estimated to increase by 1.79% in next year. EPS is likely to shrink at an annualized rate of -5.14% for next 5-years, compared to annual growth of 20.07% made by the stock over the past 5-years.
Stock get a Buy rating from BofA Securities on March 17, 2023.
